Research programme: antifungals - Basilea

Drug Profile

Research programme: antifungals - Basilea

Latest Information Update: 16 Mar 2009

Price : $50

At a glance

  • Originator Basilea Pharmaceutica
  • Class
  • Mechanism of Action Cell wall inhibitors; DNA synthesis inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Mycoses

Most Recent Events

  • 16 Mar 2009 Preclinical development is ongoing in Switzerland
  • 12 Feb 2007 Preclinical development is ongoing
  • 01 Jul 2003 Preclinical trials in Mycoses in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top